CR4056 is a first‐in‐class imidazoline‐2 (I2) receptor ligand characterized by potent analgesic activity in different experimental animal models of pain. In a recent phase II clinical trial, CR4056 effectively reduced pain in patients with knee osteoarthritis. In the present study, we investigated the effects of CR4056 on PKCε translocation in vitro and on PKCε activation in vivo in dorsal root ganglia (DRG) neurons.
CR4056, a powerful analgesic imidazoline‐2 receptor ligand, inhibits the inflammation‐induced PKCε phosphorylation and membrane translocation in sensory neurons
V. Vellani,C. Sabatini,C. Milia,G. Caselli,M. Lanza,O. Letari,L. Rovati,Chiara Giacomoni
Published 2020 in British Journal of Pharmacology
ABSTRACT
PUBLICATION RECORD
- Publication year
2020
- Venue
British Journal of Pharmacology
- Publication date
2020-01-01
- Fields of study
Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-75 of 75 references · Page 1 of 1
CITED BY
Showing 1-8 of 8 citing papers · Page 1 of 1